Evaluation of Choroidal Thickness During Pregnancy Using Enhanced Depth Imaging Optical Coherence Tomography
Launched by GAIA HOSPITAL · Dec 30, 2013
Trial Information
Current as of May 27, 2025
Unknown status
Keywords
ClinConnect Summary
Pregnant women in the last trimester and age-matched healthy controls have an Optical Coherence Tomography (OCT) image taken on the OCT Spectralis® device.
A map of the choroid in the macular area is constructed automatically. Choroidal thickness and volume are calculated for the 9 subfields defined by the Early Treatment Diabetic Retinopathy Study (ETDRS).
A comparative analysis between the two groups will be performed. As a secondary outcome measure, the change in choroidal thickness of the pregnant group of women will be assessed at 6 months postpartum by comparison to the 3rd trimeste...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- Pregnant women:
- • uncomplicated pregnancy in the third trimester (from 28 weeks of gestation)
- For both groups:
- • no systemic or ocular disease
- • absence of systemic medication other than prenatal vitamins
- • no smoking habits
- • emmetropia or a small refractive error (spherical equivalent \<1.5 diopters)
- Exclusion Criteria:
- • any of the above
About Gaia Hospital
Gaia Hospital is a leading clinical trial sponsor dedicated to advancing medical research and enhancing patient care through innovative studies. With a focus on ethical practices and patient safety, Gaia Hospital collaborates with healthcare professionals and institutions to design and execute rigorous clinical trials across various therapeutic areas. Committed to generating high-quality data, the organization employs cutting-edge methodologies and technologies to facilitate the development of new therapies and improve health outcomes. Through its relentless pursuit of excellence, Gaia Hospital strives to contribute significantly to the global medical community and foster a healthier future for all.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vila Nova De Gaia, , Portugal
Patients applied
Trial Officials
Renata Rothwell, Dr
Principal Investigator
Department of Opthalmolgy, Centro Hospitalar Vila Nova de Gaia/Espinho
Sofia Fonseca, Dr
Principal Investigator
Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia/Espinho
Marisa Oliveira, Dr
Principal Investigator
Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia/Espinho
Lígia Ribeiro, Dr
Principal Investigator
Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia/Espinho
Dália Meira, Dr
Principal Investigator
Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia/Espinho
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials